Fidaxomicin (Dificlir®)

Assessment Status Assessment process complete
Drug Fidaxomicin
Brand Dificlir®
Indication For the treatment of CDI also known as CDAD in adult patients. Rapid Review
Assessment Process
Rapid review commissioned 09/03/2012
Rapid review completed 23/03/2012
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended.
Full pharmacoeconomic assessment commissioned by HSE 05/12/2012
NCPE assessment completed 05/02/2013
NCPE assessment outcome Reimbursement recommended.

Fidaxomicin (Dificlir®) may be considered a cost-effective use of resources. It should be prescribed according to the recommendations outlined in the recently updated National Clostridium difficile Guidelines (due to be completed in February 2013


Technical Summary